Full-Time

Vice President

Information Technology

Xaira Therapeutics

Xaira Therapeutics

51-200 employees

AI-powered protein design for therapeutics

Compensation Overview

$300k - $325k/yr

+ Bonus + Equity

San Bruno, CA, USA

In Person

Category
IT & Security (2)
,
Required Skills
Microsoft Azure
Threat modeling
Machine Learning
Vulnerability Analysis
AWS
Risk Management
Google Cloud Platform
Requirements
  • 15+ years of progressive IT leadership, including 5+ years as the senior IT leader (VP, CIO, or equivalent) at a high-growth technology company
  • Proven experience owning both IT operations and security without a dedicated CISO
  • Deep expertise across cloud platforms (GCP, AWS, or Azure), enterprise architecture, SaaS ecosystems, and modern endpoint management
  • Working knowledge of cybersecurity principles, risk frameworks, and compliance programs sufficient to lead the function with credibility
  • Demonstrated ability to lead effectively in uncharted territory, setting direction and adapting as the business evolves
  • Strong analytical and data-driven approach to decision-making
  • Excellent executive communication skills, with the ability to present to and influence a board of directors
  • Bachelor's degree in Computer Science, Information Systems, Engineering, or equivalent practical experience
Responsibilities
  • Define and own the company's IT roadmap across cloud infrastructure, enterprise applications, end-user computing, networking, and AI-powered systems purpose-built for drug discovery and development
  • Make architectural decisions with long-term scalability in mind, not just near-term need
  • Lead the company's AI adoption strategy across the enterprise, identifying where AI and machine learning tools can meaningfully accelerate research workflows, computational biology pipelines, and clinical operations
  • Embed AI-driven automation into how the company works at every level, from IT operations and security to scientific data workflows, reducing manual overhead and giving researchers more time to do science
  • Identify and adopt emerging technologies in the life sciences AI space that create meaningful competitive advantage in speed and precision
  • Ensure the reliability, performance, and scalability of all enterprise systems including the AI, machine learning, and high-performance computing platforms that power drug discovery
  • Build and maintain cloud-first infrastructure that can support the significant compute and data demands of AI-driven research without becoming a bottleneck to scientific progress
  • Own incident management processes including root cause analysis, post-mortems, and follow-through on remediation
  • Establish and enforce SLAs, OKRs, and operational standards with clear accountability
  • Serve as the company's senior security leader in the absence of a CISO, owning the full security posture across network, endpoint, identity, cloud, and application layers
  • Lead all compliance programs including SOC 2, ISO 27001, GDPR, CCPA, and applicable life sciences regulatory requirements
  • Build a proactive security culture that encompasses threat modeling, vulnerability management, incident response, and employee awareness
  • Report regularly to executive leadership and the board on risk, security posture, and mitigation plans
  • Make informed decisions on the trade-offs between operational speed and security risk
  • Recruit, develop, and retain a strong IT organization with the depth to scale alongside the business
  • Build a culture of accountability, professional growth, and operational excellence
  • Develop strong internal talent and succession planning so the organization is resilient at every level
  • Act as a trusted technology advisor to the CEO, CFO, and broader leadership team
  • Partner with Engineering, Finance, Legal, People, and Operations to ensure IT functions as a strategic business enabler
  • Communicate technical strategy and risk in clear, accessible terms for non-technical stakeholders
  • Own and manage the IT budget with a focus on both fiscal discipline and strategic investment
  • Develop and manage key vendor relationships and negotiate enterprise agreements that support long-term business flexibility
  • Ensure technology spending is purposeful and tied to measurable business outcomes
Desired Qualifications
  • Experience at a scaled technology or life sciences company
  • Proven hands-on experience with AI/ML infrastructure, LLM tooling, and intelligent automation at enterprise scale
  • A track record of driving company-wide AI adoption, not just evaluating tools but leading the organizational change that makes adoption stick
  • Experience scaling IT through rapid organizational growth
  • CISSP, CISM, or equivalent security credential
  • MBA or advanced technical degree

Xaira Therapeutics uses artificial intelligence to transform drug discovery and development. It builds a pipeline of protein- and antibody-based therapeutics by combining generative AI models from the IPD lab (notably RFdiffusion and RFantibody) with large, multidimensional biological data. The company designs novel proteins and antibodies from scratch to target difficult, previously undruggable biology, then validates and evolves these molecules through iterative data generation that improves its biological foundation models. Unlike many entrants that offer research services, Xaira aims to own and advance its own therapeutic pipeline across multiple modalities, rather than solely providing platforms. The goal is to deliver effective new medicines faster and with a lower chance of failure by integrating AI-driven design, expansive data, and expert leadership.

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$1B

Headquarters

Brisbane, California

Founded

2023

Simplify Jobs

Simplify's Take

What believers are saying

  • Rachel Lane closed Genentech and Sanofi partnerships at Belharra, now drives Xaira deals.
  • Focus on inflammatory diseases aligns with high-priority pharma therapeutic targets.
  • 73,075 sq ft San Francisco expansion by July 2025 supports rapid scaling.

What critics are saying

  • Isomorphic Labs' $600M Series A in March 2025 erodes Xaira's first-mover edge.
  • Xaira's $1B burn rate triggers liquidity crisis without Series B by mid-2027.
  • Public X-Atlas release lets Recursion reverse-engineer models within 12 months.

What makes Xaira Therapeutics unique

  • Xaira leverages RFdiffusion and RFantibody from David Baker's IPD for de novo protein design.
  • X-Cell model with 4.9 billion parameters predicts perturbations on 25.6 million transcriptomes.
  • X-Atlas/Pisces dataset is largest public genome-wide CRISPRi Perturb-seq resource.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Xaira Therapeutics who can refer or advise you

Benefits

Flexible Work Hours

Stock Options

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

2%
Business Wire
Mar 26th, 2026
Xaira Therapeutics appoints Rachel Lane as SVP to lead business development and AI drug discovery partnerships

Xaira Therapeutics has appointed Rachel Lane as Senior Vice President of Business Development and Operations. She will oversee business development strategy and drive partnerships integrating machine learning with therapeutic development. Lane brings over a decade of biotech leadership experience as an operator and investor. Most recently, she served as Chief Business Officer at Belharra Therapeutics, where she closed major platform partnerships with Genentech and Sanofi. She previously worked at Versant Ventures and holds a PhD in Molecular Genetics and Cell Biology. This month, Xaira launched X-Cell, its virtual cell model trained on 25.6 million perturbed single-cell transcriptomes. The 4.9 billion-parameter model predicts outcomes of genetic perturbations, marking progress towards transforming drug discovery into a predictive engineering discipline.

Endpoints News
Mar 18th, 2026
With its first AI model release, xaira tests scaling laws in virtual cells.

With its first AI model release, xaira tests scaling laws in virtual cells. Senior biopharma correspondent. Biotech's best-funded AI startup detailed its first AI model on Tuesday, giving a glimpse at what it's been doing since launching out of stealth nearly... Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Fierce Biotech
Mar 17th, 2026
Xaira COO reveals $1B AI biotech targets inflammatory and immunological diseases

Xaira Therapeutics' Chief Operating Officer Jeff Jonker has revealed the AI-driven biotech is focusing its research and development efforts on inflammatory and immunological science. The disclosure marks the first detailed insight into how the company is deploying its capital since raising $1 billion in 2024. The secretive biotech has remained largely quiet about its operations since the fundraise. Jonker's comments to Fierce Biotech provide the first public glimpse into Xaira's strategic priorities as it applies artificial intelligence to drug discovery in areas the pharmaceutical industry considers high-priority therapeutic targets.

Business Wire
Mar 17th, 2026
Xaira Therapeutics launches X-Cell virtual cell model trained on 25.6M single-cell transcriptomes

Xaira Therapeutics has launched X-Cell, its first virtual cell model, trained on X-Atlas/Pisces, the largest genome-wide CRISPRi Perturb-seq dataset ever reported. The dataset contains 25.6 million perturbed single-cell transcriptomes across seven cellular contexts, more than three times larger than Xaira's previous dataset. X-Cell uses a diffusion language model architecture with 4.9 billion parameters, making it the largest causal perturbation model to date. Unlike traditional autoregressive models, it iteratively refines predictions by progressively replacing control gene expression values with perturbed values, improving accuracy with each step. The model demonstrates state-of-the-art performance in predicting genetic perturbation outcomes, including unseen experiments across different cell types and laboratories. Xaira is making a subset of the dataset and model available to the scientific community.

Business Wire
Jul 9th, 2025
Xaira Therapeutics Announces the Appointment of Jeff Jonker as President and Chief Operating Officer

Xaira Therapeutics announces the appointment of Jeff Jonker as President and Chief Operating Officer.